Form 4: Haemonetics CEO Exercises Stock Options and Disposes of Shares for Tax Obligations
SEC Form 4
Christopher Simon, President & CEO of Haemonetics Corp, exercised stock options and disposed of shares to cover tax obligations on June 6, 2024.
Summary
- On June 6, 2024, Christopher Simon, the President & CEO of Haemonetics Corp, exercised non-qualified stock options to acquire 104,516 shares of common stock at a price of $41.64 per share.
- The exercised options were granted in 2017 and were scheduled to expire after June 6, 2024.
- Following the transaction, Simon directly owns 362,542 shares of Haemonetics Corp common stock.
- Additionally, 71,335 shares were disposed of to cover tax obligations and the exercise price of the options at a price of $87.38.
Sentiment
Score: 5
Explanation: This is a routine Form 4 filing related to executive compensation and does not indicate any significant positive or negative sentiment.
Industry Context
Executive stock option exercises and subsequent share disposals for tax purposes are a common practice in publicly traded companies. This filing provides transparency into the transactions of a key executive at Haemonetics Corp.
Key Dates
| Date | Description |
|---|---|
| 06/06/2018 | Date from which options vested in annual increments of 25%. |
| 06/06/2024 | Date of stock option exercise and share disposal. |
| 06/07/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.